Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Regadenoson + Optison is a combination used in cardiac imaging procedures, particularly for myocardial perfusion and echocardiography. Regadenoson is a selective adenosine A2A receptor agonist that induces coronary vasodilation, increasing blood flow to the heart and helping identify areas of reduced perfusion due to coronary artery disease. Optison (perflutren protein-type A microspheres) is an ultrasound contrast agent that enhances the visualization of cardiac structures during echocardiography by opacifying the left ventricle and improving delineation of endocardial borders. This combination may be used in stress echocardiography protocols where regadenoson acts as a pharmacologic stress agent and Optison improves image quality[1][2][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on regadenoson + optison.